Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sophocarpine is a tetracyclic quinazoline alkaloid derived from the foxtail-like sophora herb (*Sophora alopecuroides* L.) and its seeds. It possesses a broad range of pharmacological properties, including anti-tumor, anti-inflammatory, antioxidant, and antifibrotic effects. In preclinical oncology research, sophocarpine has demonstrated the ability to inhibit the progression of glioblastoma multiforme (GBM) by upregulating the tumor suppressor PTEN and subsequently downregulating the PI3K/Akt signaling pathway, leading to cell cycle arrest and apoptosis. In metabolic studies, it has shown efficacy in alleviating hepatocyte steatosis in models of non-alcoholic steatohepatitis (NASH) by activating the AMPK signaling pathway and modulating adipocytokine synthesis. Furthermore, sophocarpine is being investigated for the treatment of pulmonary hypertension (PH), where it appears to reduce pulmonary artery pressure and inflammatory responses while restoring the balance of pulmonary artery remodeling.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sophocarpine.